John Bridgeman

Director of Cell Therapy Research at Instil Bio

Speaker

John undertook his PhD in 2004 under the supervision of Dr. David Gilham and Prof. Robert Hawkins at the University of Manchester. During this time his main interest was uncovering the signalling and molecular interactions of chimeric antigen receptors (CAR) and development of novel costimulatory CARs.

In 2010 John moved to the labs of Prof. David Price and Prof. Andrew Sewell at Cardiff University where he focussed on T-cell receptor (TCR) gene transfer, using it as a tool to understand biological phenomena such as alloreactivity and TCR cross-reactivity, as well as further developing adoptive cell therapy strategies. John is currently Director of Discovery Research at Instil Bio and has been developing novel engineering strategies for Tumour Infiltrating Lymphocyte (TIL) therapy.